BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30740876)

  • 1. Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance.
    Glass AS; Dall'Era MA
    BJU Int; 2019 Nov; 124(5):730-737. PubMed ID: 30740876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?
    Luzzago S; Petralia G; Musi G; Catellani M; Alessi S; Di Trapani E; Mistretta FA; Serino A; Conti A; Pricolo P; Nazzani S; Mirone V; Matei DV; Montanari E; de Cobelli O
    Clin Genitourin Cancer; 2019 Apr; 17(2):88-96. PubMed ID: 30527286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review.
    Gómez Rivas J; Giganti F; Álvarez-Maestro M; Freire MJ; Kasivisvanathan V; Martinez-Piñeiro L; Emberton M
    Eur Urol Focus; 2019 Sep; 5(5):799-806. PubMed ID: 29525382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging in prostate cancer detection and management: a systematic review.
    Monni F; Fontanella P; Grasso A; Wiklund P; Ou YC; Randazzo M; Rocco B; Montanari E; Bianchi G
    Minerva Urol Nefrol; 2017 Dec; 69(6):567-578. PubMed ID: 28488844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
    Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR
    Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What to expect from a non-suspicious prostate MRI? A review.
    Fiard G; Norris JM; Nguyen TA; Stavrinides V; Olivier J; Emberton M; Moore CM
    Prog Urol; 2020 Dec; 30(16):986-999. PubMed ID: 33008718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
    Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
    BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
    Mamawala MK; Meyer AR; Landis PK; Macura KJ; Epstein JI; Partin AW; Carter BH; Gorin MA
    BJU Int; 2020 Jun; 125(6):861-866. PubMed ID: 32039537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.
    Cantiello F; Russo GI; Kaufmann S; Cacciamani G; Crocerossa F; Ferro M; De Cobelli O; Artibani W; Cimino S; Morgia G; Damiano R; Nikolaou K; Kröger N; Stenzl A; Bedke J; Kruck S
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):206-220. PubMed ID: 30487646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
    Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
    Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
    Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?
    Bryant RJ; Yang B; Philippou Y; Lam K; Obiakor M; Ayers J; Chiocchia V; Gleeson F; MacPherson R; Verrill C; Sooriakumaran P; Hamdy FC; Brewster SF
    BJU Int; 2018 Nov; 122(5):794-800. PubMed ID: 29645347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.
    An JY; Sidana A; Choyke PL; Wood BJ; Pinto PA; Türkbey İB
    Balkan Med J; 2017 Sep; 34(5):388-396. PubMed ID: 28990929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review.
    Cantiello F; Manno S; Russo GI; Cimino S; Privitera S; Morgia G; Cicione A; Damiano R
    Anticancer Agents Med Chem; 2018; 18(7):925-930. PubMed ID: 29303080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
    Chu CE; Lonergan PE; Washington SL; Cowan JE; Shinohara K; Westphalen AC; Carroll PR; Cooperberg MR
    Eur Urol; 2020 Oct; 78(4):515-517. PubMed ID: 32631744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study.
    Patel S; Rongen JJ; Fütterer JJ; Boltyenkov A; Rovers MM
    Eur Urol Oncol; 2018 Dec; 1(6):476-483. PubMed ID: 31158091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
    Pepe P; Garufi A; Priolo G; Pennisi M
    World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of multiparametric prostate MRI in the management of prostate cancer.
    O'Connor LP; Lebastchi AH; Horuz R; Rastinehad AR; Siddiqui MM; Grummet J; Kastner C; Ahmed HU; Pinto PA; Turkbey B
    World J Urol; 2021 Mar; 39(3):651-659. PubMed ID: 32583039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.